Nodus Oncology attended the EORTC-NCI-AACR Symposium in Barcelona and were proud to present their most recent data on the development of a novel, potent PARG inhibitor NODX-010, made in partnership with the Lead Discovery Center. Displaying favourable PK and in vivo target engagement, the NODX-010 compound demonstrated tumour regression in a mouse model of breast cancer.
View or download the full poster here.
Nodus Oncology is a biotech company developing first- and best-in-class molecules focused on the DNA damage response (DDR) in patient sub-groups where molecular vulnerabilities exist. Founded by Cumulus Oncology, which contributes capital and oncology discovery as well as development expertise to the creation of new biotech companies, Nodus has received seed investment from both Cumulus Oncology and additional investors.
Further information available at: www.nodusoncology.com
The Lead Discovery Center acts as the drug discovery partner for Nodus Oncology and participates in the development of all assets in the pipeline. This close collaboration enables rapid and efficient delivery of successful programmes.
Further information available at: www.lead-discovery.de
